Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


Switching from MDIs could reduce carbon impact of inhalers and save money

Research has shown that switching just 10% of metered-dose inhalers to more environmentally friendly alternatives could save up to 58 kilotonnes of carbon emissions and £8.2m for the NHS, annually

asthma inhaler


On an individual level, the carbon footprint reduction from switching from metered-dose inhalers (pictured) could be similar to other environmentally conscious actions, such as recycling or installing home wall insulation, the researchers said

Switching patients who use metered-dose inhalers (MDIs), which contain hydrofluoroalkane propellants, to cheaper, more environmentally-friendly alternatives could lead to major cost savings, as well as reduced NHS greenhouse gas emissions, a study published in BMJ Open has shown (29 October 2019)[1]

Researchers used prescription data from 2017 in England to estimate the cost and carbon savings from switching from an MDI to a dry powder inhaler (DPI) with lower emissions, within each class of inhaler. 

They found that the annual carbon emissions in England were reduced by 58 kilotonnes for every 10% of MDIs switched to DPIs. When DPI prescribing was modelled in line with current patterns, 10% MDI switching resulted in estimated increased costs of £12.7m annually. However, when MDIs were replaced with the cheapest DPI equivalent, prescribing costs decreased by £8.2m annually. Most potential savings were due to less expensive long-acting beta-agonist/inhaled corticosteroids inhalers.

The researchers said that, on an individual level, the carbon footprint reduction was similar to other environmentally conscious actions, such as recycling or installing home wall insulation. 

“Patients, prescribers and guideline authors should carefully consider the carbon footprint of these inhalers and, where they are likely to be equally effective, prioritise low [emission] inhalers,” they concluded in BMJ Open


Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2019.20207409

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.